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Abstract
Background/Aims
Coronavirus Disease 2019 (COVID-19) has presented an unprecedented challenge for non-COVID related
clinical trials of investigational medicinal medicines (CTIMPs). These challenges are considerable for trials
run in high -risk groups, such as older adults. Clinical trials must ensure the safety of their participants,
whilst also considering the potential, and often long-term, benefits of the trial intervention to public health.
Here we sought to provide a brief perspective on the response and conduct of CTIMPs relevant to older
adults and neurology in the UK to the COVID-19 pandemic.
Methods
We performed a cross-sectional study, surveying CTIMP teams running trials broadly relevant to older adults
and neurology in the UK, as well as sponsors and Clinical Trials Units (CTU), to understand the response and
preparedness to the pandemic.
Results
Due to the pandemic, active recruitment has been suspended in more than half of the trials. The primary
driver for the temporary halt of recruitment activity was considerations of patient safety. Interestingly, the
majority of trials, sponsors and CTUs did not consider pandemic or epidemic outbreaks in their risk
assessments before January 2020.
Conclusion
These findings support the need to re-evaluate the risk-management approach whereby clinical trials
establish contingency plans for predicted but rare events to minimise the disruption to recruitment and
clinical trial delivery.
Categories: Neurology, Public Health, Other
Keywords: ctimp, response to covid-19, conduct, older adults, ageing, neurology, methodology, survey, risk
assessment, clinical trials
Introduction
Clinical trials have faced an unprecedented challenge in the light of COVID-19. On March 11, 2020, the
World Health Organisation (WHO) declared a pandemic which unequivocally complicated the conduct of
clinical trials. Importantly, urgent strategies were required to ensure the safety of enrolled participants,
weighing up the potential risks to participants of acquiring COVID-19 versus the often long-term, benefits
of the trial intervention to public health [1].
In the United Kingdom, the Health Research Authorities (HRA) published a response to the pandemic
advising clinical trials to evaluate the risk-benefit of their trial in the broader context of the impact of
COVID-19 on National Health Service (NHS) staffing, restriction of movement and government advice [2].
The National Institute for Health Research (NIHR) strategic response stated that all non-COVID-19 related
trial set-up activity would be temporarily suspended, and trials in the recruitment stage halted on a case-by-
case basis to ensure the prioritisation of COVID-19 studies and to enable the redeployment of clinical staff
to frontline care [3]. Since then, the Medicines and Healthcare products Regulatory Agency (MHRA) have
issued pragmatic guidance on how to manage clinical trials during the pandemic, including practical
guidance on the safe delivery of Investigational Medical Products (IMPs) to participants in self-isolation,
remote monitoring of trials, protocol deviations and ensuring timely and appropriate measures for
pharmacovigilance [4].
Guidance issued by the major UK non-commercial funding bodies stated that funding for trials in progress
would not be affected by the temporary halt of the trial due to COVID-19, in the short term, and/or that the
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continuation of funding and no-cost extensions will be assessed on a case-by-case basis [5-7]. We recognised
that responses and interpretation of these directives varied on both a trial and institutional level. Therefore,
we sought to describe and understand the decisions and action in response to COVID-19 for clinical trials of
investigational medicinal products (CTIMPs) that were relevant to older adults and those with neurological
conditions. These groups were chosen as a subset of those classed by the UK government as 'clinically
vulnerable people' who were advised to take particular care to minimise contact with others outside their
household [8].
This study aimed to determine the response to the COVID-19 pandemic at; a) clinical trial management
level and, b) an institutional level. We sought to determine the degree to which the pandemic impacted trial
activities. As well, we set out to understand the significant drivers behind decisions affecting the running of
CTIMP trials and the pandemic preparedness in terms of pre-existing risk assessments.
Materials And Methods
This is a retrospective, cross-sectional survey of clinical trials taking place in the UK. Ethics approval was
received from the University of Bristol on the 5th May 2020 (reference no- 104302).
The European Union Drug Regulating Authorities Clinical Trials (EudraCT) Clinical Trial Register database
was searched on May 8, 2020 using advanced search terms defined as studies in the UK (Country), Elderly
(Age range), Ongoing, Prematurely ended, Restarted or Temporarily halted (Trial status) and Phase I, II and
II (Trial phase). Gender selection was not specified. The study included trials that opened between March 1,
2015, and March 16, 2020. The search yielded a total of 2034 trials.
The results were screened based on the patient population for conditions primarily affecting or relevant to
older adults or neurology. The following conditions and studies were excluded: alcohol and substance abuse-
induced disorders of the liver and lungs, anaesthesia, asthma, cystic fibrosis, dermatology, endocrinology
including type 2 diabetes, gastrointestinal and metabolic disorders, haematology, infectious diseases, ITU
admission, oncology, post-surgical interventions, psychiatric disorders that were not secondary to a known
neurological condition, rare genetic disorders, rheumatology, trauma and transplant studies.
A total of 265 CTIMPs met the inclusion criteria and were emailed an invite to take part in the study. Emails
were obtained from publicly available sources, including trial registries and websites. The person responding
on behalf of the CTIMP completed electronic consent before participating. CTIMPs were surveyed on their
response to COVID-19 concerning recruitment, IMP management and follow-up activity. We explicitly
enquired as to whether the CTIMP risk assessment referenced pandemic management before the pandemic
(i.e. before January 2020).
The sponsor organisations of the 265 CTIMPs were identified via EudraCT and invited to take part using
contact details via publicly available sources such as trial registries. This survey included a total of 149
sponsor invitations (given that some sponsors provide support to more than one study). Also, 46 clinical trial
units (CTUs) who are fully registered with the UK Clinical Trials Research Network (UKCTRN) were identified
via the UKCTRN website. Of these, seven CTUs specialised in areas beyond the scope of the trial
criterion (e.g. paediatrics or cancer research) and were excluded. A total of 39 CTUs were invited to take part
in the survey.
Sponsors and CTUs were surveyed on the advice provided to trials concerning recruitment during the
COVID-19 pandemic as well as preparedness in terms of crisis management plans or risk assessment
considering the effect of a pandemic on trial activity. We also collected data on the number of CTIMPs
supported by the sponsors and CTUs, excluding COVID-19.
The results are presented as percentages and descriptive statistics.
Results
The highest response rate was received from CTUs (46% response rate), compared to the response rates from
trials (12% response rate) and sponsors (7% response rate) which were markedly lower. This is illustrated in
Figure 1.
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FIGURE 1: Consort diagram of the approached trials, clinical trials units
and sponsors.   
CTIMPs- clinical trials of investigational medicinal medicines; CTUs- Clinical Trials Units; UKCRC CTU- UK
Clinical Research Collaboration Clinical Trials Units; EudraCT- European Union Drug Regulating Authorities
Clinical Trials
Trial characteristics
Of the 265 invited CTIMPs, 34 trials took part in the survey. The majority of the responses pertained to trials
in the fields of Neurology or Psychiatry (44%) followed by Cardiology (41%) with the remaining trials falling
under respiratory, ophthalmology or trauma in older adults. 5 trials were single-centre trials, and 29 trials
were multicentre. 14 trials were international with sites in the UK, whilst 20 were UK based.
On the 16th of March 2020, when the UK Government announced the ‘Stay Home’ directive, of the 34 trials,
3 were in set-up, 16 trials were actively recruiting, 2 trials were suspended, 12 had completed recruitment, 1
trial was stopped permanently.
Overall, 24/34 (71%) trial teams had considered alternative ways to deliver the trial in order to reduce the
risk to participants and/or healthcare staff. Of these 15/34 trials (44%) were able to implement changes to
deliver the trial during COVID-19. Seven trials (21%) reported that they did consider this but did not
implement the changes because the institution, funder or other organisation such as the NHS Trust had
requested the suspension of the trial. Alternative methods of delivery were considered by 2 trial teams (6%)
who were unable to implement these changes and in one case this was not considered to be applicable to the
trial. Nine trial teams (26%) suggested that they had not considered alternative ways of delivering the trials.
Impact of COVID-19 on recruitment
Sixteen out of 34 trials (47%) temporarily halted recruitment during the pandemic, 4/34 trials (12%)
continued recruitment with modification to procedures, and the remaining 14 trials (41%) were not actively
recruiting e.g. studies in the follow -up phase. Data on recruitment decisions as well as the primary factor for
the decision is shown in Figure 2. Of the trials that halted recruitment, the majority of 9/16 (56%) identified
participant safety as the most important factor in the decision. Seven trials halted recruitment as directed by
the sponsor (4/16 (25%)) or by an NHS Trust (n=3, (19%)). The decision halt recruitment was driven by
several factors. Patient safety and staff considerations that included e.g. healthcare staff redeployment were
independent factors in 11/16 trials (69%). Institutional guidance from the sponsor influenced decision
making in 8/16 trials (50%), and an NHS Trust directive influenced 7/16 trials (44%). Guidance from funders
had less bearing influencing the decision in only 2/16 (5%) trials. Furthermore, logistics such as drug delivery
was a factor in decision making in only 5/16 trials (31%). Other factors that were considered included the
risks associated with treatment, data integrity/validity considerations and participant benefit of treatment.
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FIGURE 2: Trial decisions on recruitment during COVID-19
The first panel (A) shows the distribution of trials that continued or halted recruitment. The second panel (B)
shows the primary factor for the decision to halt recruitment during COVID-19 and the third panel (C) shows
the primary factor in the decision to continue recruitment during the pandemic.
NHS- National Health Service
Of the four trials which continued recruitment during COVID-19, the primary driver in 3/4 (75%) of trials
was potential participant benefit of treatment and participant safety 1/4 (25%). Concerning the factors
influencing the decision to continue recruitment with modified procedures, a single trial identified
participant benefit of the treatment, and one identified the risk associated with treatment withdrawal as
influencing the decision. In 3/4 (75%) trials, funding was a factor. 
Impact on the Investigational Medicinal Product intervention
The impact of COVID-19 on IMP regimes is shown in Figure 3. For participants enrolled in trials, 13/34
(38%) made no changes to the IMP regime. 3/34 (9%) temporarily discontinued the IMP, and 3/34 trials (9%)
reported that they prolonged or extended the treatment duration. 7/34 trials (21%) were not administrating
the IMP at the time. 6/34 trials (18%) changed the logistics of the IMP management to allow participants to
be titrated, infused or receive the IMP via post as to avoid the need to attend face-to-face appointments or
collections.
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FIGURE 3: Adjustments to the regime or protocol for the investigational
medicinal product.
IMP- Investigational Medical Products
Free-text feedback highlighted that the decision regarding the IMP regime continuation or alteration was
driven by clinical and/or practical considerations for the participants.
Follow up assessments
Data on follow up assessments are shown in Figure 4. Thirty-two trials had follow-up assessments. Of the 32
trials, 21 trials (66%) had telephone follow-ups. 19/32 trials (59%) had face-to-face follow-ups at a hospital,
clinical or research centre. Three trials (9%) had face-to-face visits at home, and 7/32 trials (22%) were
paper-based assessment (e.g. questionnaires). One trial reported using video-conferencing for follow-up
assessments. Half of the trials reported that they were planning to continue to follow up activity with
modified procedures (17/32 trials, 53%), whilst 4/32 trials (13%) planned to continue to follow up as planned
and 4/32 trials (13%) planned to continue to follow up as without modification to the procedure, but with
delayed timelines. Three trials (9%) reported a temporary halt to the follow-up activity. The remaining trials
had no change to the follow-up activity either because the trial was in set up or the follow up had been
completed.
FIGURE 4: Follow up assessments.
Follow up assessments reported by trials (A). Note some trials may have more than one type of assessment.
The trials adjustment of follow up activity in response to COVID-19 (B). F2F: Face-to-face
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Trial Risk Assessment
None of the trials surveyed identified 'epidemic', 'pandemic' or other 'public health emergency' as listed on
the trial risk assessment. Twenty-seven trials (79%) stated that their risk assessment did not list these terms,
whilst 7/34 (21%) trials were unsure. This data is shown in Figure 5.
FIGURE 5: Risk assessments.
Risk assessments including reference to  ‘pandemic’ and/or ‘epidemic’ for Trials (A), CTUs (B), and Sponsors
(C), respectively.
CTU- Clinical Trial Units
CTU response
Eighteen CTUs responded to the survey and were supporting 17 (range 0 and 14 per unit) actively recruiting
CTIMPs on March 16 2020. Four CTUs had CTIMPs that remain actively recruiting (excluding COVID-19
studies), with 3 CTIMPs being relevant to older adults.
CTU level guidance in response to the COVID-19 crisis advocated halting new recruitment and continue to
follow-ups in 7/18 units (39%). Eight CTUs (44%) indicated that the trial team (trial managers or chief
investigators) should evaluate the risk-benefit of their trial with regards to continuing or halting
recruitment. Two units (11%) encouraged continued recruitment where possible. These data are illustrated
in Figure 6.
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FIGURE 6: Advice on recruitment.
Advice on recruitment to trial teams in response to COVID-19 by CTUs (top panel (A), n=18) and Sponsors
(lower panel (B), n=11).
CTU- Clinical Trial Units
Prior to January 2020, 4/18 (22%) CTUs had an action plan or a crisis management plan in place describing
the steps to be taken in the case of a pandemic (or epidemic), 4/18 (22%) CTUs reported non-specific
contingency plans or guidance was in place for unexpected events but not specific to a pandemic (or
epidemic), and 8/18 (44%) CTUs had no pandemic (or epidemic) management plan.
One CTU reported pandemic or epidemic prior to January 2020 mentioned in their risk assessment at both
trial and management level. Three CTUs (17%) reported mention of pandemic or epidemic in their risk
assessment prior to January 2020 but only at the management level. The remaining 14/18 (78%) CTUs did
not mention pandemic or epidemic in their risk assessment prior to January 2020. This data is illustrated in
Figure 5.
Preparedness of Sponsors
Eleven sponsors replied to the survey. Of these, three were commercial sponsors, and 8 were non-
commercial sponsors. On March 16 2020, the sponsors supported a total of 23 actively recruiting CTIMPs
(range 0-4 per unit). Of these 2 CTIMPs remained actively recruiting with no suspension of activities
excluding any COVID-19 studies.
Two sponsors (18%) encouraged recruitment to continue where possible, four sponsors (36%) advised to halt
new recruitment but continue to follow up activity, and three sponsors (27%) advised investigators to
suspend all non-COVID related trial activity. The remaining two reported that the response was either led by
the NHS trust or did not give specific advice to CTIMPs as no CTIMP was open. These data are shown in
Figure 6.
Prior to January 2020, 3/11 (27%) sponsors had an action plan or a crisis management plan in place
describing the steps to be taken in the case of a pandemic (or epidemic). One sponsor reported non-specific
contingency plans were in place, but not specific to a pandemic. Seven sponsors (64%) reported that they
had no pandemic (or epidemic) management plan in place prior to January 2020.
Three sponsors (27%) reported pandemic or epidemic prior to January 2020 mentioned in their risk
assessment at but only at management level. None of the sponsors reported mention of pandemic or
epidemic prior to January 2020 in the risk assessment at both trial and management level (0%). The
remaining eight sponsors (73%) did not mention pandemic or epidemic in their risk assessment prior to
January 2020. This data is shown in Figure 5.
Discussion
During the pandemic, there was a rapid shift in focus and prioritisation to research that tackled COVID-
19 [2-4]. The redeployment of resources and expertise led to activity in CTIMPs in other 'non-COVID'
disease areas being suspended [3]. 
To further understand and quantify this broader impact, we surveyed clinical trial teams and sought data
from supporting CTUs and sponsors. We identified >2000 potentially eligible trials. The response rates from
clinical trials and sponsors were low and we anticipate that this may have been a different function of the
pandemic. The majority of those that responded paused recruitment during COVID-19, but follow-up
activity and IMP regimes continued mostly unchanged. This suggests that whilst recruitment activity was
heavily affected, trials were mostly able to proceed or accommodate changes which allowed them to
continue the trial activity for those participants enrolled before the COVID-19 pandemic. Such changes
included modification to the follow -up procedures, adjusting time scales for follow-ups and in some cases
changing the logistics of the IMP to allow for home delivery to participants. Participant safety or potential
benefit was the primary driver that determined the course of action taken during the pandemic.
Very few institutions (CTUs and sponsors) had considered the pandemic impact on trials before January
2020. At a trial level, no risk assessment mentioned pandemic or epidemic, suggesting little preparatory
activity to mitigate the risk was undertaken before the outbreak.
The UK National Risk Register of Civil Emergencies 2017 [9] documented an increased likelihood of
emerging infectious diseases relative to the year 2015. However, the impact severity (ranked 3 out of 5) and
likelihood of occurrence (ranked 4 out of 5) in the five years following the report's publication was
considered equivalent to low air quality, heat waves and space weather. Nonetheless, the government
continued to acknowledge the high impact severity (5 out of 5) of a potential flu pandemic. However, the
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likelihood was considered equivalent to that of other emerging infectious diseases (4 out of 5). Despite the
relatively high likelihood of a (flu or emerging infectious disease) pandemic on the national risk register, this
risk was primarily omitted in risk assessments before January 2020 at both trial and institutional level.
Perhaps unsurprisingly, little guidance exists as to where the responsibility falls for assessing and adapting
risk mitigation protocols for national and/or systemic risks not specific to the trial environment, such as the
emergence of a pandemic.
As such, the preparedness of trials to respond and adapt to an epidemic, pandemic or local outbreak of
infectious diseases which increases the risk to the vulnerable populations appears, in retrospect, to be a
worthwhile exercise. For example, most trials were able to adapt follow up procedures to allow some trial
activity to continue whilst recruitment was suspended in more than half of the trials actively recruiting prior
to the pandemic.
Strengths and limitations
The study provides insight which may be helpful to the future planning and preparedness of trials not only
to a potential second wave of COVID-19 but also to other local and national infectious disease outbreaks.
The survey focused on the key aspects of trial activity for CTIMPs; namely, recruitment, follow up and IMP
management. This allowed us to assess specifically the type of trial activity impacted by the novel health
emergency. The study was conducted in a subgroup of people who are listed as 'high clinical risk' by UK
government officials. Therefore, the CTIMPs surveyed would encompass those who are most likely to be
impacted by the pandemic.
The low response rate from trials and sponsors is such that we would seek to see the findings reproduced and
considered in other populations and disease areas before definitive conclusions could inform future policy.
Whilst we purposefully, but pragmatically, limited the search criteria to include studies relevant to older
adults and neurology, some trials may have been omitted which could be of relevance given the criteria
search on EudraCT, e.g. studies which were relevant to older adults but did not tag 'Elderly' on the database.
The survey was conducted in May 2020, and therefore it was issued more than one month after the UK
government's 'Stay Home' directive [8]. Whilst the timing of the survey would have allowed trials to respond
to the COVID-19 crisis, it may have fallen at a time where trial managers, chief investigators and sponsors
were busy preparing trials to restart activity in light of the gradual easing of restrictions nationwide. The
survey did not explore the process or timeline of the response to the pandemic. Some CTUs, sponsors and
trials may have adapted and prepared in advance of the WHO declaration of SARS-nCOV2 outbreaks as a
pandemic on March 11, 2020 [10] or the government restriction announced on March 16, 2020 [8]. For
example, the surveys asked about the mention of a pandemic on risk assessments before January 2020 only;
that is mentions which preceded the WHO declaring COVID-19 a public health emergency of international
concern (PHEIC) [10].
Future impacts
COVID-19 has necessitated a realignment of focus on the immediate public health crisis facing the UK
population. An indirect consequence of this is the potentially negative impact on the existing portfolio of
clinical trials running in non-COVID conditions. Our work has demonstrated that rapid changes and
flexibility of delivery partially mitigated the impact.
A new framework for risk-adapted approaches to clinical trials may be needed until a vaccine, or efficacious
treatment is available [1,4]. Trial teams are exploring novel ways of delivering clinical trials including
recruitment approaches, clinical assessments and IMP monitoring. These novel methods have emerged from
an urgent need during an unprecedented time. The longer-term adaptation and implementation of such
measures show promise to promote trial inclusivity for a heterogeneous population of older adults with and
without chronic conditions which are both under-represented in clinical research and potentially at most
significant risk of acquiring COVID-19 infection. 
Conclusions
The majority of trials temporarily halted recruitment during the pandemic. Despite a lack or delayed
recognition of the risk that a pandemic presented at all levels of trial oversight, the rapid implementation of
novel delivery methods holds promise for the future. Our findings call for a re-evaluation of the risk-
management approach to evaluate whether clinical trials may be able to find contingency plans in the future
to allow less disruption to trial activity.
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